Vertex Pharmaceuticals Archives

woman holding her wrist pain because using smartphone or computer long time. De Quervain's tenosynovitis, Intersection Symptom, Carpal Tunnel Syndrome or Office syndrome concept. To illustrate tendon damage

News & Features

Next-Generation Non-Opioid Pain Relievers Advance

Malorye Branca -

February 15, 2024

An illustration of a CRISPR-Cas9 gene editing protein cutting a DNA helix

News & Features

In Another Win for CRISPR, FDA Approves Casgevy for Beta Thalassemia

Malorye Branca -

January 17, 2024

Scientist pipetting sample into a vial for DNA testing

News & Features

Newcomer Tome Acquires Replace TX in $250M Gene Editing Deal

Malorye Branca -

January 3, 2024

Sickle Cell disease - 3D Illustration of sickled blood cells on a dark background

News & Features

Two Gene Therapies for Sickle Cell Disease Get FDA Nod, Including First Ever CRISPR-Based Therapy

Malorye Branca -

December 11, 2023

News & Features

U.K. Approves Vertex/CRISPR Tx’s Casgevy for Sickle Cell and Beta Thalassemia

Malorye Branca -

November 16, 2023

Senior woman with shoulder pain. Elderly woman is enduring awful ache. Shoulder Pain In An Elderly Person. Senior lady with shoulder pain

News & Features

Vertex Publishes on Its Promising Non-Opioid Pain Reliever

Malorye Branca -

August 7, 2023

News & Features

One and Done? How CRISPR Is Changing the Clinical Outlook for Multiple Diseases

Kathy Vuksanaj -

June 5, 2023

News & Features

Using the Epigenome to Guide Development of Gene Edited Therapies

Helen Albert -

May 31, 2023

Blood clot made of red blood cells, platelets and fibrin protein strands. Thrombus

News & Features

Bluebird Tightens Sickle Cell Race with BLA for Gene Therapy

Malorye Branca -

April 25, 2023

News & Features

Vertex Taps Mammoth’s CRISPR Tech in Gene Therapy Deal Worth up to $695M

Alex Philippidis -

October 26, 2021

12 Page 1 of 2

Study of Brain Related Genes Showcases Value of Diverse Biobanks

SHORE’d-up: Heart Transplant Rejection Diagnostic Outperforms Biopsies

Radiofrequency-Based Ablation Shows 85.7% Success Rate Treating Atrial Fibrillation

Bayer’s Elinzanetant Shines in Phase III, Heating up Menopause Drug Market

Combining Blood Test with Clinical Score Offers Breakthrough for Stroke Detection

Vertex Pharmaceuticals

Next-Generation Non-Opioid Pain Relievers Advance

In Another Win for CRISPR, FDA Approves Casgevy for Beta Thalassemia

Newcomer Tome Acquires Replace TX in $250M Gene Editing Deal

Two Gene Therapies for Sickle Cell Disease Get FDA Nod, Including First Ever CRISPR-Based Therapy

U.K. Approves Vertex/CRISPR Tx’s Casgevy for Sickle Cell and Beta Thalassemia

Vertex Publishes on Its Promising Non-Opioid Pain Reliever

One and Done? How CRISPR Is Changing the Clinical Outlook for Multiple Diseases

Using the Epigenome to Guide Development of Gene Edited Therapies

Bluebird Tightens Sickle Cell Race with BLA for Gene Therapy

Vertex Taps Mammoth’s CRISPR Tech in Gene Therapy Deal Worth up to $695M

Related Content

Metsera Launches with $290M to Develop Next Generation Weight Loss Products

Investigational mRNA-Based Vaccine May Represent New Approach to Treating Pancreatic Cancer

Gilead and Xilio Ink Potential $640M+ Deal around “Next-Generation” Immunotherapy

First MYC Inhibitor Shows Promise in Human Clinical Trial